Compare Diageo plc (DEO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Quest Diagnostics Inc — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while Quest Diagnostics Inc trades at $229.97 (market cap $25.48B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Quest Diagnostics Inc for 56 Days on average.
| DEO | DGX | |
|---|---|---|
Market Cap | $47.67B | $25.48B |
Volume | 893,372 | 941,866 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $247.45 |
52-Week Low | $72.47 | $173.49 |
Typical Hold Time | 66 Days | 56 Days |
Enterprise Value | $68.09B | $31.23B |
Dividend Yield | 2.3% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical indicators and strong analyst support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and positive cash flow generation. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, though revenue declined to $19.6B in 2026 with margin compression.
The stock presents a compelling turnaround opportunity with analyst consensus favoring bullish sentiment (48.65% buy ratings). Key catalysts include cost-saving initiatives and brand revitalization, while risks involve US market challenges, regulatory scrutiny in India, and ongoing margin pressure. The current valuation at 27.91 P/E appears reasonable given the growth potential.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
